ClinicalTrials.Veeva

Menu

The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population

A

Asfendiyarov Kazakh National Medical University

Status

Completed

Conditions

Atopic Dermatitis

Treatments

Genetic: DNA analysis

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

This is a GWAS study that aims to identify possible candidate genes associate to atopic dermatitisby exploring single nucleotide polymorphism (SNP) in a group of atopic dermatitis, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with atopic dermatitis

Full description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Enrollment

600 patients

Sex

All

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Persons with various forms of a confirmed diagnosis of atopic dermatitis;
  • The age of the patients is from 18 to 45+ years;
  • Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.
  • Persons who are able and willing to provide written informed consent;
  • Persons capable and willing to comply with the research protocol;

Exclusion criteria

  • Persons under the age of 18;
  • Patients with severe concomitant systemic diseases, including cardiovascular, respiratory, hepatic and renal failure
  • Patients with severe infectious processes (sepsis, abscess, hepatitis B and C, HIV)
  • Persons with mental illness.
  • Persons taking corticosteroid drugs, immunosuppressants within the last month;
  • Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
  • Pregnant or lactating women;
  • Tuberculosis of any localization in the active phase and in history;
  • Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
  • Severe and decompensated course of endocrine diseases;
  • Autoimmune diseases;
  • Systemic diseases;
  • Oncological diseases;

Trial design

600 participants in 2 patient groups

Experimental group:
Description:
Patients with atopic dermatitis
Treatment:
Genetic: DNA analysis
Control group
Description:
Patients without atopic dermatitis
Treatment:
Genetic: DNA analysis

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems